Compare Stocks: DTIL, AURA, PHAR, and CLYM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AURA Aura Biosciences	$7.72 +7.5%	$6.92	$4.73 ▼ $9.53	$742.32M	0.4	393,857 shs	577,448 shs
CLYM Climb Bio	$14.00 +12.3%	$12.30	$1.54 ▼ $14.41	$714.07M	0.08	1.06 million shs	1.43 million shs
DTIL Precision BioSciences	$7.42 -0.7%	$7.35	$3.53 ▼ $9.62	$192.74M	1.27	361,521 shs	328,717 shs
PHAR Pharming Group	$10.69 +0.0%	$12.78	$9.62 ▼ $21.34	$755.56M	-0.01	10,536 shs	3,735 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AURA Aura Biosciences	+7.52%	+8.58%	+9.82%	-8.10%	+12.87%
CLYM Climb Bio	+12.27%	+15.04%	+4.32%	+23.13%	+700.00%
DTIL Precision BioSciences	-0.67%	+6.00%	-19.78%	-3.51%	+54.26%
PHAR Pharming Group	+0.05%	-0.60%	-25.82%	-17.68%	-13.06%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AURA Aura Biosciences	$7.72 +7.5%	$6.92	$4.73 ▼ $9.53	$742.32M	0.4	393,857 shs	577,448 shs
CLYM Climb Bio	$14.00 +12.3%	$12.30	$1.54 ▼ $14.41	$714.07M	0.08	1.06 million shs	1.43 million shs
DTIL Precision BioSciences	$7.42 -0.7%	$7.35	$3.53 ▼ $9.62	$192.74M	1.27	361,521 shs	328,717 shs
PHAR Pharming Group	$10.69 +0.0%	$12.78	$9.62 ▼ $21.34	$755.56M	-0.01	10,536 shs	3,735 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AURA Aura Biosciences	+7.52%	+8.58%	+9.82%	-8.10%	+12.87%
CLYM Climb Bio	+12.27%	+15.04%	+4.32%	+23.13%	+700.00%
DTIL Precision BioSciences	-0.67%	+6.00%	-19.78%	-3.51%	+54.26%
PHAR Pharming Group	+0.05%	-0.60%	-25.82%	-17.68%	-13.06%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AURA Aura Biosciences	2.25	Hold	$20.50	165.54% Upside
CLYM Climb Bio	3.07	Buy	$22.08	57.74% Upside
DTIL Precision BioSciences	2.60	Moderate Buy	$32.25	334.64% Upside
PHAR Pharming Group	2.20	Hold	$38.67	261.88% Upside

Current Analyst Ratings Breakdown

Latest DTIL, AURA, PHAR, and CLYM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/3/2026	CLYM Climb Bio	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$23.00
8/3/2026	CLYM Climb Bio	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Moderate Buy	$23.00
8/3/2026	DTIL Precision BioSciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/3/2026	PHAR Pharming Group	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$37.00 ➝ $38.00
7/31/2026	PHAR Pharming Group	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/30/2026	PHAR Pharming Group	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
7/27/2026	CLYM Climb Bio	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$17.00 ➝ $20.00
7/17/2026	CLYM Climb Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/14/2026	AURA Aura Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/9/2026	DTIL Precision BioSciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
6/29/2026	AURA Aura Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 8/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AURA Aura Biosciences	N/A	N/A	N/A	N/A	$2.16 per share	N/A
CLYM Climb Bio	N/A	N/A	N/A	N/A	$3.36 per share	N/A
DTIL Precision BioSciences	$34.26M	5.59	N/A	N/A	$4.03 per share	1.84
PHAR Pharming Group	$376.13M	2.01	$0.20 per share	53.23	$3.82 per share	2.80

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AURA Aura Biosciences	-$106.19M	-$1.74	N/A	N/A	N/A	N/A	-78.12%	-64.08%	8/12/2026 (Estimated)
CLYM Climb Bio	-$59.85M	-$0.78	N/A	N/A	N/A	N/A	-31.45%	-30.39%	N/A
DTIL Precision BioSciences	-$45.72M	-$3.67	N/A	N/A	N/A	-96.73%	-85.37%	-37.34%	N/A
PHAR Pharming Group	$2.85M	$0.12	89.04	35.62	N/A	2.51%	3.40%	1.90%	N/A

Latest DTIL, AURA, PHAR, and CLYM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	AURA Aura Biosciences	-$0.3750	N/A	N/A	N/A	N/A	N/A
8/6/2026	Q2 2026	CLYM Climb Bio	-$0.2093	-$0.18	+$0.0293	-$0.18	N/A	N/A
8/6/2026	Q2 2026	DTIL Precision BioSciences	-$0.8040	-$1.26	-$0.4560	-$1.26	$0.74 million	N/A
7/30/2026	Q2 2026	PHAR Pharming Group	$0.0630	$0.02	-$0.0430	$0.02	$99.52 million	$90.20 million
5/21/2026	Q1 2026	AURA Aura Biosciences	-$0.40	-$0.50	-$0.10	-$0.50	N/A	N/A
5/11/2026	Q1 2026	AURA Aura Biosciences	-$0.40	-$0.50	-$0.10	-$0.50	N/A	N/A
5/7/2026	Q1 2026	CLYM Climb Bio	-$0.26	-$0.20	+$0.06	-$0.20	N/A	N/A
5/7/2026	Q1 2026	PHAR Pharming Group	$0.05	-$0.07	-$0.12	-$0.07	$92.06 million	$72.45 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AURA Aura Biosciences	N/A	N/A	N/A	N/A	N/A
CLYM Climb Bio	N/A	N/A	N/A	N/A	N/A
DTIL Precision BioSciences	N/A	N/A	N/A	N/A	N/A
PHAR Pharming Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AURA Aura Biosciences	N/A	7.09	7.09
CLYM Climb Bio	N/A	27.86	27.86
DTIL Precision BioSciences	0.29	14.02	14.02
PHAR Pharming Group	0.34	3.01	2.06

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AURA Aura Biosciences	96.75%
CLYM Climb Bio	69.76%
DTIL Precision BioSciences	37.99%
PHAR Pharming Group	0.03%

Insider Ownership

Company	Insider Ownership
AURA Aura Biosciences	1.90%
CLYM Climb Bio	2.60%
DTIL Precision BioSciences	2.70%
PHAR Pharming Group	2.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AURA Aura Biosciences	50	103.39 million	101.42 million	Not Optionable
CLYM Climb Bio	9	57.26 million	55.77 million	N/A
DTIL Precision BioSciences	200	25.80 million	25.11 million	No Data
PHAR Pharming Group	280	70.78 million	69.31 million	Not Optionable

DTIL, AURA, PHAR, and CLYM Headlines

Recent News About These Companies

Securities Fraud Investigation Into Pharming Group N.V. (PHAR) Announced - Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

August 5 at 11:59 PM | tmcnet.com

Securities Fraud Investigation Into Pharming Group N.V. (PHAR) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R.

August 5 at 3:16 PM | businesswire.com

Pharming Group (NASDAQ:PHAR) Shares Gap Up - Time to Buy?

August 5 at 11:59 AM | marketbeat.com

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Pharming Group (PHAR)

August 5 at 10:05 AM | globenewswire.com

Pharming Group (NASDAQ:PHAR) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says

August 5 at 1:06 AM | americanbankingnews.com

PHAR Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Pharming Group (PHAR)

August 4 at 2:09 PM | tmcnet.com

Pharming Group to participate in Canaccord Genuity 46th Annual Growth Conference

August 4 at 9:08 AM | finance.yahoo.com

Canaccord Genuity Group Forecasts Strong Price Appreciation for Pharming Group (NASDAQ:PHAR) Stock

August 3, 2026 | marketbeat.com

HC Wainwright Lowers Earnings Estimates for Pharming Group

August 3, 2026 | americanbankingnews.com

Q3 EPS Estimates for Pharming Group Lowered by HC Wainwright

August 3, 2026 | marketbeat.com

Pharming Group (NASDAQ:PHAR) Shares Gap Down After Earnings Miss

August 2, 2026 | americanbankingnews.com

Pharming Group (NASDAQ:PHAR) Hits New 12-Month Low Following Weak Earnings

August 1, 2026 | americanbankingnews.com

Pharming Group (NASDAQ:PHAR) Posts Earnings Results, Misses Expectations By $0.04 EPS

July 31, 2026 | marketbeat.com

Pharming Group Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Pharming Group (PHAR)

July 31, 2026 | prnewswire.com

Pharming Group (NASDAQ:PHAR) Shares Gap Down Following Weak Earnings

July 31, 2026 | marketbeat.com

Pharming Group N.V. (PHAR) Q2 2026 Earnings Call Transcript

July 30, 2026 | seekingalpha.com

Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader ...

July 30, 2026 | markets.businessinsider.com

Pharming Group下调2026年营收指引3000万美元，销售疲软拖累业绩

July 30, 2026 | cn.investing.com

Pharming Group mist Q2 2026 omzetverwachting, aandeel daalt 22%

July 30, 2026 | nl.investing.com

Pharming Group (NASDAQ:PHAR) Sets New 12-Month Low Following Weak Earnings

July 30, 2026 | marketbeat.com

Pharming Group Q2 Earnings Call Highlights

July 30, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

DTIL, AURA, PHAR, and CLYM Company Descriptions

Aura Biosciences NASDAQ:AURA

$7.72 +0.54 (+7.52%)

Closing price 08/6/2026 04:00 PM Eastern

Extended Trading

$7.70 -0.02 (-0.26%)

As of 05:33 AM Eastern

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Climb Bio NASDAQ:CLYM

$14.00 +1.53 (+12.27%)

Closing price 08/6/2026 04:00 PM Eastern

Extended Trading

$13.69 -0.31 (-2.21%)

As of 05:25 AM Eastern

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

Precision BioSciences NASDAQ:DTIL

$7.42 -0.05 (-0.67%)

Closing price 08/6/2026 04:00 PM Eastern

Extended Trading

$7.42 0.00 (-0.07%)

As of 08/6/2026 04:21 PM Eastern

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Pharming Group NASDAQ:PHAR

$10.68 +0.01 (+0.05%)

Closing price 08/6/2026 03:58 PM Eastern

Extended Trading

$10.87 +0.18 (+1.72%)

As of 08/6/2026 04:35 PM Eastern

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DTIL, AURA, PHAR, and CLYM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DTIL, AURA, PHAR, and CLYM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DTIL, AURA, PHAR, and CLYM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DTIL, AURA, PHAR, and CLYM Company Descriptions

Aura Biosciences NASDAQ:AURA

Climb Bio NASDAQ:CLYM

Precision BioSciences NASDAQ:DTIL

Pharming Group NASDAQ:PHAR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DTIL, AURA, PHAR, and CLYM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DTIL, AURA, PHAR, and CLYM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DTIL, AURA, PHAR, and CLYM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DTIL, AURA, PHAR, and CLYM Company Descriptions

Aura Biosciences NASDAQ:AURA

Climb Bio NASDAQ:CLYM

Precision BioSciences NASDAQ:DTIL

Pharming Group NASDAQ:PHAR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools